Professor, Internal Medicine, University of Michigan Medical School
Gastroenterology
Dr. Anna S. Lok, MD
|
|
Give Review
Anna practices Gastroenterology. She over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Anna S. Lok, MD is a published doctor. She published 68 publications, including: 'Entecavir safety and effectiveness in a national cohort of treatment-nave chronic hepatitis B patients in the US - the ENUMERATE study.' Anna accepts all Medicare patients.
Publications
- Diabetes and prediabetes in patients with Hepatitis B residing in North America.
- Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic Hepatitis B patients in the US - the ENUMERATE study.
- Present and future therapies of Hepatitis B: From discovery to cure.
- Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug Treatments.
- Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and HBV Genotype.
- A comparative study of patients' knowledge about Hepatitis C in the United States and in urban and rural China.
- A Comparative Study of Patients' Attitudes Toward Clinical Research in the United States and Urban and Rural China.
- Changes in characteristics of Hepatitis C patients seen in a liver centre in the United States during the last decade.
- Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring - predictors and predictive models of disease prog...
- Is It More Cost-effective for Patients With Chronic Hepatitis B to Have a Trial of Interferon Before Considering Nucleos(t)ide Analogue Therapy?
- Outcomes of Patients with Chronic Hepatitis B Who do not Meet Criteria for Antiviral Treatment at Presentation.
- Does suppression of HBV replication by antiviral therapy confer the same benefit as host Immune control of HBV?
- Progress in Hepatitis b: A 30-year journey through three continents.
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for Hepatitis C virus genotype 1 null responders.
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
- Potential Benefit of Telbivudine on Renal Function Does Not Outweigh Its High Rate of Antiviral Drug Resistance and Other Adverse Effects.
- Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma.
- Should treatment of Hepatitis B patients be based solely on liver fibrosis?
- Management of Hepatitis B: My Practice and how it relates to the Guidelines.
- CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation.
- Impaired Virion Secretion by Hepatitis B Virus Immune Escape Mutants and its Rescue by Wild-Type Envelope Proteins or a Second-Site Mutation.
- Combination nucleos(t)ide analogue as initial treatmentfor chronic Hepatitis B: Have we put this to rest?
- Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
- Hepatitis: Long-term therapy of chronic hepatitis B reverses Cirrhosis.
- Effectiveness of Hepatitis B treatment in clinical practice.
- Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
- YKL-40 genetic polymorphisms and the risk of liver Disease progression in patients with advanced fibrosis due to chronic hepatitis C.
- Preliminary study of two antiviral agents for Hepatitis C genotype 1.
- Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?
- Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation.
- Hospital Readmissions Among Patients With Decompensated Cirrhosis.
- Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C.
- Burden of Cirrhosis on older americans and their families: Analysis of the health and retirement study.
- Authorship: Who Should Be Included and How Should It Be Determined?
- Response to Dr. Ridruejo's letter.
- Response to letter of Dr. Raimondo et al regarding HEP-10-1609.R2.
- Reply to: "Does adherence to Hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?"
- Histologic outcomes in Hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.
- Antiviral therapy for chronic Hepatitis B.
- Should antiviral treatment be extended to patients with chronic Hepatitis B and mildly elevated alanine aminotransferase?
- Renal outcomes after liver transplantation in the model for end-stage liver Disease era.
- An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
- Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
- Characterization of genotype-specific carboxyl-terminal cleavage sites of Hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme.
- Do guidelines preclude Hepatitis B patients from receiving treatment?
- Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with Hepatitis B antiviral resistance.
- Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver Disease.
- Prolonged therapy of advanced chronic Hepatitis C with low-dose peginterferon.
- Should liver biopsies be performed on all Hepatitis B carriers?
- Update on viral Hepatitis: 2007.
- Modified Charlson comorbidity index for predicting survival after liver transplantation.
- Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic Hepatitis B.
- Sustained virologic response to therapy of recurrent Hepatitis C after liver transplantation is related to early virologic response and dose adherence.
- Update on viral Hepatitis: 2006.
- Navigating the maze of Hepatitis B treatments.
- Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma.
- Clinical relevance of cognitive scores in Hepatitis C patients with advanced fibrosis.
- Natural history of chronic Hepatitis B virus infection: what we knew in 1981 and what we know in 2005.
- Liver transplantation for erythropoietic protoporphyria liver Disease.
- The maze of treatments for Hepatitis B.
- One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatoHepatitis: a pilot study.
- Prognosis of hepatocellular carcinoma: comparison of 7 staging Systems in an American cohort.
- Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.
- New treatment of chronic Hepatitis B.
- A simple noninvasive index can predict both significant fibrosis and Cirrhosis in patients with chronic hepatitis C.
- Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver Disease in american patients.
- NAFLD may be a common underlying liver Disease in patients with hepatocellular carcinoma in the United States.
Schools
University Of Hong Kong
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- ERCP (Endoscopic Retrograde Cholangiopancreatography)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Seton Hall University School of Health and Medical Sciences -
University of Hong Kong Faculty of Medicine
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1013090935 | |
| NPPES Provider LastName | LOK | |
| NPPES Provider FirstName | ANNA | |
| NPPES Provider ZIPCode | 481095362 | |
| NPPES Provider State | MI | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 694.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013090935 |
| Last Name Of The Provider | LOK |
| First Name Of The Provider | ANNA |
| View All |
Similar Doctors
|
|
Dr. Michael D. Rice, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Del Valle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amit Singal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy B. Menees, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge A. Marrero, MD |
|
|
Dr. Neil M. Sheth, MD |
|
|
Dr. Grace L. Su, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Frederick K. Askari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas D. Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shannan R. Tujios, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laurel R. Fisher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emmanuelle D. Williams, MD |